USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
Molecular Neuroimaging, L.l.c.
Address:
60 TEMPLE STREET, SUITE 8A
NEW HAVEN, CT
Phone:
(203) 401-4351
URL:
N/A
EIN:
61594851
DUNS:
20285081
Number of Employees:
58
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $2,799,642.00 8
SBIR Phase II $1,499,655.00 2
STTR Phase I $840,457.00 1
STTR Phase II $2,406,347.00 1

Award List:

DEVELOPMENT OF AN IMAGING MARKER FOR PARKINSON'S DISEASE

Award Year / Program / Phase:
2002 / SBIR / Phase I
Award Amount:
$99,755.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The development of disease modifying agents in Parkinson's disease has rapidly expanded the need for in vivo markers for diagnosis and monitoring disease progression. Dopamine transporter (DAT) imaging offers the promise of an objective measure of dopaminergic… More

An Imaging Marker for Parkinson's Disease

Award Year / Program / Phase:
2003 / SBIR / Phase II
Award Amount:
$749,655.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The development of disease modifying agents in Parkinson's disease has rapidly expanded the need for in vivo markers for diagnosis and monitoring disease progression. Dopamine transporter (DAT) imaging offers the promise of an objective measure of dopaminergic… More

Novel VMAT 2 Radioligand for Imaging Parkinson's

Award Year / Program / Phase:
2003 / SBIR / Phase I
Award Amount:
$500,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Parkinson's disease (PD) is clinically characterized by bradykinesia, rigidity, tremor, and gait disturbance that progresses slowly over many years. The pathophysiological loss of dopamine neurons is a hallmark of this disorder and has guided treatments for… More

AZA BICYCLO NONANE SEROTONIN TRANSPORTER RADIOTRACERS

Award Year / Program / Phase:
2004 / SBIR / Phase I
Award Amount:
$499,990.00
Agency:
HHS
Principal Investigator:
Gilles D. Tamagnan
Abstract:
DESCRIPTION (provided by applicant): The goal of this research project is to define the structure and radioactive label for ligands that will permit quantitative measurement of serotonin transporter (5-HTT) sites in living brain by external imaging with positron or single-photon emission… More

Indole Glyoxylamides Peripheral Benzodiazepine Receptor

Award Year / Program / Phase:
2006 / SBIR / Phase I
Award Amount:
$500,000.00
Agency:
HHS
Principal Investigator:
Abstract:
The goal of this research project is to define the structure and radioactive label for ligands that will permit quantitative measurement of the peripheral benzodiazepine receptor (PBR ) in living brain by external imaging with positron (PET) or single photon (SPECT) emission tomography. A… More

Development of Automated Software Program for the Analysis of Parkinson's Diesease Dopamine Transporter Scans

Award Year / Program / Phase:
2007 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
DOE
Principal Investigator:
Abstract:
This project will develop a fast, automated, and accurate software processing package that will objectively yield striatal quantitative uptake values for evaluating Parkinson's disease (PD) diagnosis and progression. This fully automated, Objective Striatal Analysis (OSA) package will evaluate… More

Detection of Amyloid Plaques

Award Year / Program / Phase:
2007 / SBIR / Phase I
Award Amount:
$499,897.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The goal of this research project is to define the structure and radioactive label for ligands that will per-mit quantitative measurement of amyloid sites in living brain by external imaging with positron (PET) or singl e photon (SPECT) emission tomography. A… More

Automated Parkinson's Disease Dopamine Transporter Scan Analysis Fast Track

Award Year / Program / Phase:
2007 / STTR / Phase I
Award Amount:
$840,457.00
Agency:
HHS
Principal Investigator:
Research Institution:
INSTITUTE FOR NEURODEGENERATIV
RI Contact:
N/A
Abstract:
DESCRIPTION (provided by applicant): We hypothesize that for a class of dopamine transporter SPECT agents, an automated software processing package can be developed, which will objectively yield striatal quantitative uptake values for evaluating Parkinson' s disease (PD) diagnosis and progression.… More

In vivo evaluation of a new ligand with picomolar affinity for the serotonin tran

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$500,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The goal of this research project is to validate in humans a new ligand with picomolar affinity for the serotonin transporter. It will permit quantitative measurement of serotonin transporter (5- HTT) sites in living br ain by imaging with single photon emission… More

Development of Automated Software Program for the Analysis of Alzheimer's Disease Beta-Amyloid Scans

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
DOE
Principal Investigator:
Abstract:
This project will develop a fast, automated, and accurate software processing package that will objectively yield beta-amyloid uptake values for evaluating Alzheimer¿s disease diagnosis and progression. This fully-automated, Objective and Generalized new Radiotracer Analysis (OGRE) package will… More

Development of Automated Software Program for the Analysis of Alzheimer's Disease Beta-Amyloid Scans

Award Year / Program / Phase:
2009 / SBIR / Phase II
Award Amount:
$750,000.00
Agency:
DOE
Principal Investigator:
Abstract:
Clinical trials are now underway for the commercialization of radiopharmaceuticals that target beta amyloid, a compound that requires quantification for the diagnosis of Alzheimer¿s Disease (AD). This project will develop an automated software processing package that will objectively yield… More

Computational Tools for Research in Neuroscience, Behavioral Science and Mental H

Award Year / Program / Phase:
2012 / STTR / Phase II
Award Amount:
$2,406,347.00
Agency:
HHS
Principal Investigator:
George Zubal – 203-401-4300
Research Institution:
UNIV OF TX SW MED CTR-DALLAS
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): We propose to develop a software package to automatically evaluate a subject's beta amyloid PET scan (using either C11-PIB, F18-florbetaben, or F18-florbetapir, F18-flutemetamol) by normalizing the subject's scan, masking away non-gray matter tissue… More